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SUPPLEMENTARY NOTES
ABSTRACT (200 words of the most significant findings and erase this text)
We have in the first funding year successfully generated the mouse strains required for the proposed experiments. In particular, we have generated FMRP mutant mice that also harbor the TauEGFP allele which allows the identification and purification of induced neuronal (iN) cells. We have also successfully established mouse embryonic fibroblast and tail-tip derived fibroblast cultures from these mice. Moreover, we successfully generated iN cells from these mice and characterized them molecularly. They are also being analyzed electrophysiologically in the Chen lab (see her report). Moreover, we have made very good progress in converting also human fibroblasts into iN cells. Systematic screening of additional transcription factors has revealed that the addition of NeuroD1 greatly enhances the efficiency to convert human fibroblasts into iN cells and in this condition we were also able to generate cells that are synaptically competent. However, the efficiencies are still much lower than using mouse cells and we are currently trying to improve these efficiencies. We have generated iN cells from various somatic cells including mouse hepatocytes and more importantly also from human skin fibroblasts. The main hypothesis of this proposal is that these iN cells can be used to study molecular features of FXS in both the mouse model as proof of principle as well as using human cells.
SUBJECT TERMS (
Body
We perform this project in close collaboration with the Partner PI of the grant, Dr. Lu Chen. Some parts of the Specific Aims are done in her lab, while others are performed in mine. Please refer to her progress report regarding the tasks that her lab is responsible for. I will describe the progress that our group has made under each Specific Aim in the following:
Specific Aim 1. Characterization of synaptic properties of iN cells derived from fibroblasts of Fmr1 KO mice (Chen and Wernig lab)
Task 1. Convert fibroblasts from Fmr1 KO mice to iN cells We have accomplished this goal and used the same approach to convert wild type mouse fibroblasts (Vierbuchen et al., 2010 Nature) . Moreover, it became clear that it is not only required to convert Fmr1 KO fibroblasts to iN cells, but we need in addition a genetic live label of iN cells. To that end we bred the Fmr1 KO mice to Tau-EGFP Knock-in mice. Tau is a neuronal-specific gene and therefore, GFP-positive cells derived from fibroblasts unambiguously labels iN cells. This allows to study these cells not only in isolation, but also in co-cultures with astrocytes (a condition known to dramatically improve synaptic maturation and synaptogenesis) or together with primary neurons, derived from the neonatal or fetal hippocampus or neocortex. 
Specific Aim 2. Generation of iN cells from FXS patients (Wernig lab) Task 3. Derive human iN cells from human embryonic fibroblasts
We are very happy to report that we have been successful to derive iN cells from human fetal fibroblasts that are fully functional, i.e. have both active membrane properties (such as action potentials) and show synaptic input from surrounding neurons (other iN cells or primary neurons), thus are synaptically competent. We had to use an additional transcription factor: NeuroD1 to convert human cells which was not required for the mouse cells. Figure 3 shows the results of the screen that identified NeuroD1 as critical additional factor. Figure 4 shows an example of a human fetal fibroblast-derived iN cells and an example trace demonstrating synaptic input. 
Task 4. Derive human iN cells from human skin fibroblasts
We have successfully generated iN cells also from early postnatal human foreskin fibroblasts. In principle we were able to find cells with the same functional characteristics as the fetal fibroblast-derived iN cells (as shown in Figs. 3&4) . However, while the efficiency of getting Tuj1-positive cells was similar, the yield of fully synaptically competent cells was much lower. Therefore, we are working on systematic ways now to improve the protocol (testing seeding densities, various media conditions, as well as small molecule inhibitors to block and activate various signaling pathways in isolation and combination).
Task 5. Derive human iN cells representing different neuronal subtypes from human skin fibroblasts (Wernig lab, months 15-24) As planned we have not yet begun these experiments as we feel first, we need to improve the reprogramming efficiencies with human postnatal and eventually adult fibroblasts. 
Reportable Outcomes
We have prepared and submitted a manuscript that describes the generation of iN cells from human pluripotent stem cells. This manuscript is currently under review at Neuron.
Conclusion
Our research achievements have been so far as planned and we will continue to work on the tasks as originally proposed. We are not sure how fast we will be able to optimize the human fibroblast-iN cell conversion, but as of now everything is quite "on track". In addition, we have developed an intriguing alternative approach to generate iN cells from iPS cells that will work for sure, in case our original plan to use fibroblast-iN cells from human patients turns out to require more time to optimize.
